Literature DB >> 20592783

Review of the safety and feasibility of rapid infusion of rituximab.

Jill Atmar1.   

Abstract

Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.

Entities:  

Year:  2010        PMID： 20592783      PMCID： PMC2835489          DOI： 10.1200/JOP.200001

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  13 in total

1.  Rapid-infusion rituximab in lymphoma treatment.

Authors:  M Provencio; S Cerdeira; F Bonilla; A Sánchez; P España
Journal:  Ann Oncol       Date:  2005-12-01       Impact factor: 32.976

Review 2.  A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.

Authors:  Arturo Molina
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

3.  Rapid infusion of rituximab over 60 min.

Authors:  Mark Tuthill; Tim Crook; Tim Corbet; Jenny King; Andrew Webb
Journal:  Eur J Haematol       Date:  2009-01-29       Impact factor: 2.997

Review 4.  Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.

Authors:  Christine H Chung
Journal:  Oncologist       Date:  2008-06

5.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

6.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

7.  Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting.

Authors:  Laurie H Sehn; Jane Donaldson; Allison Filewich; Catherine Fitzgerald; Karamjit K Gill; Nancy Runzer; Barb Searle; Sheila Souliere; John J Spinelli; Judy Sutherland; Joseph M Connors
Journal:  Blood       Date:  2007-01-23       Impact factor: 22.113

8.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

Authors:  Robert Marcus; Kevin Imrie; Andrew Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; Joäo Raposo; Andrew Jack; Paul Smith
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

9.  Rapid infusion rituximab changing practice for patient care.

Authors:  Ali Al Zahrani; Nagwa Ibrahim; Ahmed Al Eid
Journal:  J Oncol Pharm Pract       Date:  2009-01-26       Impact factor: 1.809

10.  A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function.

Authors:  Marco Siano; Erika Lerch; Laura Negretti; Emanuele Zucca; Delvys Rodriguez-Abreu; Michel Oberson; Leda Leoncini; Oreste Mora; Cristiana Sessa; Augusto Gallino; Michele Ghielmini
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531
View more
  9 in total

1.  Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.

Authors:  Meryem Can; Fatma Alibaz-Öner; Sibel Yılmaz-Öner; Pamir Atagündüz; Nevsun İnanç; Haner Direskeneli
Journal:  Clin Rheumatol       Date:  2012-10-11       Impact factor: 2.980

2.  A Retrospective Study on Infusion-Related Reactions to Rituximab in a Heterogeneous Pediatric Population.

Authors:  Clément Legeay; Henrique Bittencourt; Elie Haddad; Laurence Spiesser-Robelet; Valérie Thépot-Seegers; Roxane Therrien
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Sep-Oct

3.  A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.

Authors:  Daisuke Tsutsumi; Tatsuya Hayama; Katsuhiro Miura; Akihiro Uchiike; Shinya Tsuboi; Susumu Otsuka; Yoshihiro Hatta; Yukinaga Kishikawa
Journal:  Int J Clin Pharm       Date:  2021-12-11

Review 4.  Rituximab therapy in nephrotic syndrome: implications for patients' management.

Authors:  Aditi Sinha; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2013-01-22       Impact factor: 28.314

5.  Rapid-Infusion Rituximab in a Pediatric Population.

Authors:  Kelly J Gaffney; Elizabeth M Dahl; Michael P Stanton; Elizabeth Starek; Anthony S Zembillas
Journal:  J Pediatr Pharmacol Ther       Date:  2020

6.  Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience.

Authors:  Jan Miroslav Hartinger; Veronika Satrapová; Zdenka Hrušková; Vladimír Tesař
Journal:  Eur J Hosp Pharm       Date:  2018-02-28

7.  The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.

Authors:  Mark Bishton; Scott Marshall; Jatinder Harchowal; Gilles Salles; Camille Golfier; Alessandra Tucci; Alicia Rodriguez Fernández; Jose Javier Sanchez Blanco; Monica Bocchia; SooKyoung Kim; Young Nam Lee; Pier Luigi Zinzani
Journal:  Hematol Oncol       Date:  2022-03-17       Impact factor: 4.850

8.  Rapid infusion rituximab for maintenance therapy: is it feasible?

Authors:  Jolly Patel; Melissa Ho; Viet Ho; Celeste Bello; Benjamin Djulbegovic; Lubomir Sokol; Gene Wetzstein
Journal:  Leuk Res Treatment       Date:  2013-10-31

9.  Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.

Authors:  Charles H Pritchard; Maria W Greenwald; Joel M Kremer; Norman B Gaylis; William Rigby; Steve Zlotnick; Carol Chung; Birgit Jaber; William Reiss
Journal:  BMC Musculoskelet Disord       Date:  2014-05-24       Impact factor: 2.362
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.